U.S. Stock Movement Update: Agape ATP surges 87%, Oriental Culture plummets 79%, multiple stocks show significant movement

Market Overview of US Stocks in the Last Hour The US stock market has shown a significant sector rotation in the past hour, with technology and pharmaceutical stocks performing particularly well. Small-cap stocks and thematic stocks have experienced large fluctuations, with noticeable capital inflows. Market sentiment is relatively active, with short-term enthusiasm rising, and some individual stocks have shown significant price movements. The stock with the largest abnormal movement in the last hour is Agape ATP, which surged 87.35%, with trading volume significantly increasing and short-term capital inflows evident, leading to heightened market sentiment. Strong stocks include: 1. SMX Security Matters: up 67.70%, with a 10-day increase of 1113.76%, driven significantly by short-term capital. 2. Grande: up 59.08%, with a 5-day increase of 58.77%, gaining market attention. 3. HeartBeam: up 52.91%, with a 6-month increase of 51.28%, showing clear capital inflows. 4. Velo3D: up 38.26%, with increased trading volume and active short-term capital. 5. Mawson Infrastructure: up 37.54%, with increased trading volume and positive market sentiment. 6. Treasure Gbl: up 26.62%, with increased trading volume driven by short-term capital. 7. CapsoVision: up 25.59%, with increased trading volume and heightened market attention. 8. Nextdoor: up 25.34%, reaching a new 60-day high, with noticeable capital inflows

Pre-market hot trades in US stocks: NovaBay Pharmaceuticals down 6.21% in pre-market; Nebius down 3.22% in pre-market

NovaBay Pharmaceuticals pre-market down 6.21%; Nebius pre-market down 3.22%; Agape ATP pre-market up 95.44%; AXIL Brands pre-market up 84.46%; Mawson Infrastructure pre-market up 49.25%

NovaBay Pharmaceuticals Reports Turnaround in Earnings

NovaBay Pharmaceuticals reported a net income of $4.455 million for Q3 2025, marking a turnaround from a $6.011 million loss in 2024. This improvement is due to income from discontinued operations after divesting eyecare and skincare businesses. Despite ongoing operating losses, the company reduced liabilities and is exploring new strategic directions, including blockchain markets, with optimism for future financial stability.

Novabay Pharmac | 10-Q: FY2025 Q3 Revenue: USD 521 K

NovaBay Pharmaceuticals Files Initial Beneficial Ownership Statement for R01 Fund LP

NovaBay Pharmaceuticals Inc. has filed an initial beneficial ownership statement, identifying R01 Fund LP as the beneficial owner. The filing is accessible via the provided link. This news was generated by Public Technologies (PUBT) using AI and is for informational purposes only, not to be considered as financial, investment, or legal advice. The original content was published by NovaBay Pharmaceuticals via EDGAR on October 20, 2025.